Altimmune (ALT) Restructuring Costs (2015)

Altimmune (ALT) reported Restructuring Costs of $26886.0 for Q4 2015, down 93.64% quarter-over-quarter from $422482.0 in Q3 2015.

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has 1 years of Restructuring Costs data on file, last reported at $26886.0 in Q4 2015.

Restructuring Costs for Q4 2015 came in at $26886.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2016 was $26886.0 (changed N/A YoY), and the FY2015 annual result was $2.5 million, changed N/A from the prior year.
Restructuring Costs retreated to $26886.0 in Q4 2015 per ALT's latest filing, from $422482.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $2.1 million in Q1 2015 and troughed at $26886.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Altimmune	336.67 Mn	336.67 Mn	-

Download Data